Evaluation of the treatment effectiveness in patients with stage IIB–IIIB ovarian cancer

Abstract

BACKGROUND: The relevance of the study is due to the urgent problem of assessing therapy effectiveness for stage IIB–IIIB ovarian cancer.

AIM: Study of patients' survival rates after surgical treatment of various forms of stages IIB–IIIB of ovarian cancer depending on a number of clinical and morphological factors.

MATERIAL AND METHODS: The material for the study was long-term observations of patients who received treatment from 2004 to 2021 at the Primorsky Regional Oncology Dispensary, the source was the medical record of an inpatient (form 003/u). The group of patients with stage IIB–IIIB ovarian cancer consisted of 107 patients, average age 50.7±11.5 years. Of these, 43 (40.2%) were women with stage IIB, 46 (43.0%) patients with stage IIIA, 3 (2.8%) patients with stage IIIA2, 15 (14.0%) patients with stage IIIB. Overall survival and progression-free survival were assessed. Statistical methods included survival analysis using the Kaplan–Meier method with the construction of survival curves, medians and standard errors of survival time, and comparison of survival between groups of patients using the log-rank test.

RESULTS: In patients with low-grade serous carcinoma, the five-year progression-free survival rate was higher than in patients with high-grade serous carcinoma (71.1±13.5 and 39.5±7.7%, respectively; p <0.01). Primary surgical treatment performed in gynecological hospitals reduced the median life expectancy and five-year survival rate by 150.0 months and 25.9% (p <0.01; RR=3.4; 95% CI=1.2–9.4). Interval cytoreduction reduced the median time to progression and five-year progression-free survival in patients with stage IIB–IIIB ovarian cancer (53.0±35.2 months and 43.7±16.5%) compared with patients underwent primary surgery (70.0±37.5 months and 57.3±6.0%). The five-year survival rate was higher in patients receiving a combination of platinum and taxanes — 94.7±5.1% (p <0.01; HR=0.2; 95% CI=0.05–0.5).

CONCLUSION: In patients with stage IIB–IIIB ovarian cancer, factors such as primary surgical treatment performed in specialized gynecological oncology hospitals and adjuvant chemotherapy with platinum drugs in combination with taxane agents statistically significantly increase survival.

Keywords

ovarian cancer / stages IIB–IIIB / surgery / overall survival

References

[1] Stewart C, Ralyea C, Lockwood S. Ovarian cancer: An integrated review. Semin Oncol Nurs. 2019;35(2):151–156. doi: 10.1016/j.sonicn.2019.02.001

[2] Stewart C., Ralyea C., Lockwood S. Ovarian cancer: An integrated review // Semin Oncol Nurs. 2019. Vol. 35, N. 2. Р. 151–156. 10.1016/j.sonicn.2019.02.001

[3] Stages of ovarian cancer: international classification. Available from: https://www.oncomedic.org Accessed: Jan 5, 2024. (In Russ.)

[4] Стадии рака яичников: международная классификация. Режим доступа: https://www.oncomedic.org Дата обращения: 15.01.2024.

[5] O'Shea AS. Clinical staging of ovarian cancer. Methods Mol Biol. 2022;2424:3–10. doi: 10.1007/978-1-0716-1956-8_1

[6] O'Shea A.S. Clinical staging of ovarian cancer // Methods Mol Biol. 2022. Vol. 2424. Р. 3–10. doi: 10.1007/978-1-0716-1956-8_1

[7] Faber MT, Horsbøl TA, Baandrup L. Trends in survival of epithelial ovarian/tubal cancer by histology and socioeconomic status in Denmark 1996–2017. Gynecol Oncol. 2022;164(1):98–104. doi: 10.1016/j.gino.2021.10.091

[8] Faber M.T., Horsbøl T.A., Baandrup L. Trends in survival of epithelial ovarian/tubal cancer by histology and socioeconomic status in Denmark 1996–2017 // Gynecol Oncol. 2022. Vol. 164, N. 1. Р. 98–104. doi: 10.1016/j.gino.2021.10.091

[9] Sekerskaya MN, Nikoghosyan SO, Kuznetsov VV, Shevchuk AS, Tamrazov RI, Aliev VA. Long-term outcomes of surgical treatment of common ovarian cancer at the stage of primary debulking. Pelvic Surgery and Oncology. 2019;(3):46–53. (In Russ.) doi: 10.17650/2686-9594-2019-9-3-46-53

[10] Секерская М.Н., Никогосян С.О., Кузнецов В.В., и др. Отдалённые результаты хирургического лечения распространённого рака яичников на этапе первичной циторедукции // Тазовая хирургия и онкология. 2019. № 3. С. 46–53. doi: 10.17650/2686-9594-2019-9-3-46-53

[11] Ministry of Health of the Russian Federation. Clinical recommendations. Ovarian cancer, fallopian tube cancer, primary peritoneal cancer — 2020–2021–2022 (31.01.2023). Available from: http://disuria.ru/_ld/13/1326_kr20C48C56C57MZ.pdf Accessed: Feb 17, 2024.

[12] Минздрав РФ. Клинические рекомендации. Рак яичников, рак маточной трубы, первичный рак брюшины — 2020–2021–2022 (31.01.2023). Режим доступа: http://disuria.ru/_ld/13/1326_kr20C48C56C57MZ.pdf Дата обращения: 17.02.2024.

[13] Washington CJ, Karanth SD, Wheeler M. Racial and socioeconomic disparities in survival among women with advanced-stage ovarian cancer who received systemic therapy. Cancer Causes Control. 2023;24:487–496. doi: 10.1007/s10552-023-01810-y

[14] Washington C.J., Karanth S.D., Wheeler M. Racial and socioeconomic disparities in survival among women with advanced-stage ovarian cancer who received systemic therapy // Cancer Causes Control. 2023. Т. 24. Р. 487–496. doi: 10.1007/s10552-023-01810-y

[15] Maslentseva NYu. Cancer incidence as an indicator of socio-economic problems. Aktual'nye problemy gumanitarnykh i estestvennykh nauk. 2015;(5-2):263–266. (In Russ.) EDN: TVPDVZ

[16] Масленцева Н.Ю. Онкозаболеваемость как показатель социально-экономических проблем // Актуальные проблемы гуманитарных и естественных наук. 2015. №5-2. С. 263–266. EDN: TVPDVZ

[17] Rumyantsev AA, Tjulandina AS, Pokataev IA, Tjulandin SA. Controversies in surgical treatment of advanced ovarian cancer. Malignant Tumours. 2017;7(3):13–22. (In Russ.) doi: 10.18027/2224-5057-2017-7-3-13-22

[18] Румянцев А.А., Тюландин А.С., Покатаев И.А., Тюландин С.А. Противоречия в хирургическом лечении распространённого рака яичников // Злокачественные опухоли. 2017. Т. 7, № 3. С. 13–22. doi: 10.18027/2224-5057-2017-7-3-13-22

[19] Gockley A, Melamed A, Bregar AJ, Clemmer JT, Birrer M, Schorge JO, Del Carmen MG, Rauh-Hain JA. Outcomes of women with high-grade and low-grade advanced-stage serous epithelial ovarian cancer. Obstet Gynecol. 2017;129(3):439–447. doi: doi: 10.1097/AOG.0000000000001867

[20] Gockley A., Melamed A., Bregar A.J., et al. Outcomes of women with high-grade and low-grade advanced-stage serous epithelial ovarian cancer // Obstet Gynecol. 2017. Vol. 129, N. 3. P. 439–447. doi: 10.1097/AOG.0000000000001867

[21] Ayhan A, Ozkan NT, Sarı ME, Celik H, Dede M, Akbayır Ö, Güngördük K, Şahin H, Haberal A, Güngör T, Arvas M, Meydanlı MM. Impact of lymph node ratio on survival in stage III ovarian high-grade serous cancer: A Turkish Gynecologic Oncology Group study. J Gynecol Oncol. 2018;29(1):e12. doi: 10.3802/jgo.2018.29.e12

[22] Ayhan A., Ozkan N.T., Sarı M.E., et al. Impact of lymph node ratio on survival in stage III ovarian high-grade serous cancer: A Turkish Gynecologic Oncology Group study // J Gynecol Oncol. 2018. Vol. 29, N. 1. Р. e12. doi: 10.3802/jgo.2018.29.e12

[23] Engelen MJ, Kos HE, Willemse PH, Aalders JG, de Vries EG, Schaapveld M, Otter R, van der Zee AG. Surgery by consultant gynecologic oncologists improves survival in patients with ovarian carcinoma. Cancer. 2006;106(3):589–598. doi: 10.1002/cncr.21616

[24] Engelen M.J., Kos H.E., Willemse P.H., et al. Surgery by consultant gynecologic oncologists improves survival in patients with ovarian carcinoma // Cancer. 2006. Vol. 106, N. 3. Р. 589–598. doi: 10.1002/cncr.21616

[25] Ledermann JA, Raja FA, Fotopoulou C, Gonzalez-Martin A, Colombo N, Sessa C. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24:24–32. doi: 10.1093/annonc/mdt333

[26] Ledermann J.A., Raja F.A., Fotopoulou C., et al. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up // Ann Oncol. 2013. Vol. 24. Р. 24–32. doi: 10.1093/annonc/mdt333

[27] Ghisoni E, Katsaros D, Maggiorotto F. A predictive score for optimal cytoreduction at interval debulking surgery in epithelial ovarian cancer: A two-centers experience. Research. 2018;11(1):42. doi: 10.1186/s13048-018-0415-y

[28] Ghisoni E., Katsaros D., Maggiorotto F. A predictive score for optimal cytoreduction at interval debulking surgery in epithelial ovarian cancer: A two-centers experience // Research. 2018. Vol. 11, N. 1. Р. 42. doi: 10.1186/s13048-018-0415-y

[29] Fagotti A, Ferrandina G, Vizzielli G, Fanfani F, Salotti V, Chiantera V, Costantini B, Margariti PA. Phase III randomised clinical trial comparing primary surgery versus neoadjuvant chemotherapy in advanced epithelial ovarian cancer with high tumour load (SCORPION trial): Final analysis of peri-operative outcome. Eur J Cancer. 2016;59:22–33. doi: 10.1016/j.ejca.2016.01.017

[30] Fagotti A., Ferrandina G., Vizzielli G., et al. Phase III randomised clinical trial comparing primary surgery versus neoadjuvant chemotherapy in advanced epithelial ovarian cancer with high tumour load (SCORPION trial): Final analysis of peri-operative outcome // Eur J Cancer. 2016. Vol. 59. Р. 22–33. doi: 10.1016/j.ejca.2016.01.017

[31] Gorodnova TV, Kotiv HB, Petrik SV, Sokolenko AP, Ivantsov AO, Guseinov KD, Ibragimov ZN, Meshkova IE, Nekrasova EA, Sidoruk AA, Smirnova OA, Bondarev NE, Lavrinovich OE, Mikaya NA, Ulrikh EA, Urmancheeva AF, Imyanitov EN, Karachun AM, Belyaev AM, Berlev IV. Cytoreductive surgery for ovarian cancer: a review of literature and analysis of the experience of the clinic for thirteen years. Voprosy onkologii. 2018;(3):353–368. (In Russ.) EDN: XWBIBF

[32] Городнова Т.В., Котив Х.Б., Петрик С.В., и др. Циторедуктивные операции при раке яичников: обзор литературы и анализ опыта клиники за тринадцать лет // Вопросы онкологии. 2018. № 3. С. 353–368. EDN: XWBIBF

Funding

Программа здравоохранения ГБУЗ «Приморский краевой онкологический диспансер»Healthcare program of the State Budgetary Healthcare Institution “Primorsky Regional Oncology Dispensary”

RIGHTS & PERMISSIONS

Eco-Vector